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Dendritic cell (DC)-based immunotherapy makes use of the DC’s ability to direct the 
adaptive immune response toward activation or inhibition. DCs perform this immune 
orchestration in part by secretion of selected cytokines. The most potent anti-inflamma-
tory cytokine interleukin-10 (IL-10) is under tight regulation, as it needs to be predomi-
nantly expressed during the resolution phase of the immune response. Currently it is not 
clear whether there is active suppression of IL-10 by DCs at the initial pro-inflammatory 
stage of the immune response. Previously, knockdown of the DC-specific transcription 
factor DC-SCRIPT has been demonstrated to mediate an extensive increase in IL-10 
production upon encounter with pro-inflammatory immune stimuli. Here, we explored 
how DC-SCRIPT contributes to IL-10 suppression under pro-inflammatory conditions 
by applying chromatin immunoprecipitation sequencing analysis of DC-SCRIPT and the 
epigenetic marks H3K4me3 and H3K27ac in human DCs. The data showed binding of 
DC-SCRIPT to a GA-rich motif at H3K27ac-marked genomic enhancers that associated 
with genes encoding MAPK dual-specificity phosphatases (DUSPs). Functional studies 
revealed that upon knockdown of DC-SCRIPT, human DCs express much less DUSP4 
and exhibit increased phosphorylation of the three major MAPKs (ERK, JNK, and p38). 
Enhanced ERK signaling in DC-SCRIPT-knockdown-DCs led to higher production 
of IL-10, which was reverted by rescuing DUSP4 expression. Finally, DC-SCRIPT-
knockdown-DCs induced less IFN-γ and increased IL-10 production in naïve T cells, 
indicative for a more anti-inflammatory phenotype. In conclusion, we have delineated 
a new mechanism by which DC-SCRIPT allows DCs to limit IL-10 production under 
inflammatory conditions and potentiate pro-inflammatory Th1 responses. These insights 
may be exploited to improve DC-based immunotherapies.
Keywords: ZnF366, erK, chromatin immunoprecipitation sequencing, dual-specificity phosphatase 4, dendritic 
cells, MaPK, Dc-scriPT, il-10
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inTrODUcTiOn
Immunotherapy has gained great success in recent years due to 
the success of checkpoint inhibitors targeting the PD-1/PD-L1 
or CTLA-4 pathways (1–4). These checkpoint inhibitors act on 
T cells, and it is widely accepted that T cells are quintessential 
in the fight against cancer. However, T cells are not capable of 
eliciting an anti-tumor response by themselves, because without 
the right instructions, the T  cells will remain naïve or become 
tolerogenic (5). The only cell type capable of efficiently educating 
naïve T cells is the dendritic cell (DC). We have come very far in 
our understanding of the role of cell surface receptors and secreted 
molecules involved in immune regulation by DCs, which has 
been exploited in therapies against cancer with promising results 
(6, 7). By contrast, information regarding intracellular regulatory 
circuits in DCs is far scarcer, and could possess potential for 
future therapeutic strategies as well.
DCs sample their environment, and sense foreign molecules 
using pattern-recognition receptors of which the toll-like recep-
tors (TLRs) are the best known (8). Activation of DCs through 
TLR-triggering is needed for upregulation of antigen-presenting 
and co-stimulatory molecules, and production of cytokines 
that direct the T  cell response toward activation (9). Thus, 
DCs hold the potential to induce either an immune-activating 
or immune-dampening response (10). Interleukin-10 (IL-10) 
has been demonstrated to play a crucial role in this process, 
by inhibiting development of pro-inflammatory Th1  cells and 
promoting development of anti-inflammatory Tr1 cells (11). 
Besides being involved in T cell education, several studies also 
reported on downregulation of MHC class II expression on 
antigen-presenting cells (APCs) and of MHC class I on tumor 
cells in cancer patients with elevated IL-10 levels in serum or 
tumors (12–18). Although high IL-10 production in cancer 
patients is associated with a poor prognosis, some recent reports 
have suggested that situations may exist in which elevated levels 
of IL-10 in cancer patients may also have beneficial effects via 
dampening the chronic inflammation in tumor microenviron-
ments and by stimulation of cytotoxicity of already activated 
CD8+ T cells (19).
In the context of APCs, we have learned a great deal about 
how IL-10 is upregulated via activation of the MAP kinase ERK 
and the transcription factor NF-κB during the resolution phase 
of an immune response (20). Whether IL-10 expression is actively 
kept in check in DCs during the initial inflammatory phase of 
the immune response is currently unknown (20). Dendritic 
cell-specific transcript (DC-SCRIPT, ZNF366) is a transcription 
factor uniquely expressed by DCs in the immune system (21–23). 
DC-SCRIPT has been shown to have a complex collection of 
functions, including nuclear receptor co-regulatory activity 
(24–29), cell cycle regulation (30), NF-κB activity modulation 
(31), and mediating induction of T cell proliferation and IFN-γ 
production (23). Most strikingly, DC-SCRIPT knockdown leads 
to a massive increase in IL-10 production after pro-inflammatory 
TLR-triggering (23, 27, 31), suggesting that DC-SCRIPT may 
participate in active suppression of IL-10. In this study. we 
explored how DC-SCRIPT contributes to the active suppression 
of IL-10 production in human activated monocyte-derived DCs.
resUlTs
Dc-scriPT Binds genomic enhancers 
near MaPK Phosphatases
In order to delineate the molecular mechanism for how 
DC-SCRIPT regulates IL-10 expression in DCs under inflamma-
tory conditions, we conducted a chromatin immunoprecipitation 
sequencing (ChIP-Seq) analysis using a DC-SCRIPT specific 
antibody on human monocyte-derived DCs. Antibodies specific 
for the epigenetic marks histone H3 lysine 4 tri-methylation 
[H3K4me3; associated with promoters of active genes (32)] and 
H3K27 acetylation (ac) [present at active enhancers and promot-
ers (33)] were taken along in the same DC samples (Figure 1; 
GEO accession number: GSE78923). To account for donor vari-
ation and dynamics, three donors were assayed, using immature, 
1 h, and 24 h TLR ligand R848 (Resiquimod)-stimulated DCs. 
Only DC-SCRIPT binding sites consistently present in all three 
donors in at least one of the assayed time points were used for 
subsequent analysis, yielding a total of 10,833 DC-SCRIPT bind-
ing sites in the human genome. Clustering of the DC-SCRIPT 
DNA binding sites with the genomic H3K27ac and H3K4me3 
histone marks in DCs displayed a 37% overlap (Figure 1A, cluster 
2–6). Out of these, 1,462 DC-SCRIPT binding sites overlapped 
with the promoter mark H3K4me3 (Figure 1A, clusters 2–4 and 
Figure 1B, top), and 2,550 DC-SCRIPT binding sites overlapped 
with histone marks characteristic for enhancers (high H3K27ac, 
low/no H3K4me3, clusters 5–6 Figures 1A,B, middle). Promoter-
associated DC-SCRIPT binding sites are henceforth referred to 
as PA-SC binding sites and enhancer-associated DC-SCRIPT 
binding sites referred to as EA-SC binding sites. The DC-SCRIPT 
binding sites that did not co-localize with either of these marks 
(Figures 1A,B, bottom) were left out from the current analysis. To 
further characterize the sequence content of the genomic locations 
where DC-SCRIPT binds, a de novo motif analysis was performed 
on the DC-SCRIPT ChIP-Seq dataset using GimmeMotifs (34). 
This unguided comparison of the DNA sequence under all the 
DC-SCRIPT binding sites, yielded a GA-rich DC-SCRIPT bind-
ing motif (Figure 1C). To validate the motif in a different and 
independent assay, we also performed in vitro cyclic amplification 
and selection of targets (CAST) in a cell-free system (Figure 1D). 
The CAST motif successfully validated the de novo motif with 
the two independently generated motifs being 78% similar 
to each other [assayed by MAST in MEME (35), Figure S1 in 
Supplementary Material]. The de novo and the in vitro motif were 
found in up to 44% of the EA-SC binding sites and 38% of the 
PA-SC binding sites, respectively (Figure S1 in Supplementary 
Material).
Previously, we have shown that in the absence of DC-SCRIPT 
there is increased NF-κB binding to the il10 enhancer (31), 
suggesting that DC-SCRIPT may also bind there. Surprisingly, 
there was no DC-SCRIPT binding site in the il10 promoter or 
any il10-associated enhancer that could explain the effect of 
DC-SCRIPT expression on IL-10 production. Genomic Regions 
Enrichment of Annotations Tool [GREAT (36)] was then used 
to get more insight into the pathways that DC-SCRIPT may 
regulate to affect IL-10 expression. The gene ontology (GO) 
FigUre 1 | Genome-wide mapping of DC-SCRIPT binding sites in human dendritic cells (DCs). Chromatin immunoprecipitation sequencing (ChIP-Seq) of human 
immature or R848 (toll-like receptors 7/8 ligand)-activated DCs using DC-SCRIPT, H3K4me3, or H3K27ac Abs (n = 3). (a) Heatmap of k-means clustering analysis 
(k = 6, Euclidean distance) of DC-SCRIPT (blue), H3K4me3 (green), and H3K27ac (purple) in 10-kb windows around DC-SCRIPT peak summits. Clusters 2–4 are 
merged into an enhancer-associated cluster; clusters 5–6 are merged into a promoter-associated cluster. The rows correspond to the peaks; the x-axis shows the 
position relative to the peak center. The intensity of the color represents the number of reads in 100-bp windows. (B) Representative UCSC Genome Browser tracks 
of a PA-SC binding site (top), an EA-SC binding site (middle), and a no mark binding site (bottom). The tracks from top to bottom show the gene annotation, the 
ChIP-Seq signal for DC-SCRIPT (blue), H3K4me3 (green), H3K27ac (purple), and input (gray). (c) de novo motif generated from DC-SCRIPT ChIP-Seq binding 
sites. (D) In vitro motif identified by cyclic amplification and selection of targets. (e) Genomic Regions Enrichment of Annotations Tool analysis of all DC-SCRIPT-
binding sites containing the GA-rich motif. The table contains the top 10 most significant terms in the gene ontology category molecular function. See also Figure S1 
and Tables S1 and S2 in Supplementary Material.
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biological process term was dominated by immune regulatory 
processes (Table S1 in Supplementary Material), reinforcing the 
previously demonstrated role of DC-SCRIPT in immune regula-
tion (23, 31). Interestingly, the molecular function GO showed 
that DC-SCRIPT  binds in the vicinity of MAPK phosphatase 
genes (Figure 1E; Table S2 in Supplementary Material). MAPK 
phosphatases are a subgroup of the dual-specificity phosphatases 
(DUSPs) and are responsible for the dephosphorylation of 
MAPKs (37). Given that the MAPK ERK previously has been 
associated with IL-10 production (20), DC-SCRIPT may there-
fore potentially regulate DUSPs to modulate IL-10 production.
Dc-scriPT Modulates the MaPK Pathway
The GREAT analysis showed that 4 out of 14 MAPK DUSPs were 
associated with a total of 9 EA-SC binding sites located on aver-
age 246 kb (range: 3–859 kb) from the transcription start site. In 
order to validate their expression in relation to DC-SCRIPT, we 
knocked down DC-SCRIPT using siRNA specific to DC-SCRIPT 
(SC-KD-DCs) or control non-targeting siRNA (Ctrl-DCs) 
(Figure  2A). The expression of the four DUSP genes that had 
DC-SCRIPT binding sites associated (DUSP1, DUSP4, DUSP5, 
and DUSP10) were assayed by RT-qPCR at different time points 
after R848 stimulation (Figures  2B–E). As a control, the well-
known ERK phosphatase DUSP6 (38), that in this study did not 
have any DC-SCRIPT binding sites associated, was also assayed 
(Figure 2F). All five assayed DUSPs were upregulated after R848 
stimulation, but only DUSP4 and DUSP6 displayed a significant 
difference in expression upon DC-SCRIPT knockdown. DUSP4 
was consistently higher expressed in Ctrl-DCs, while DUSP6 was 
consistently higher expressed in SC-KD-DCs. Since the main 
role of DUSPs is to inhibit MAPK signaling, we next assayed 
if DC-SCRIPT silencing has an impact on the signaling of the 
MAPKs. The levels of phosphorylation of the three major MAPKs: 
ERK, JNK, and p38 were assayed by western blotting (WB) 
FigUre 2 | DC-SCRIPT affects the MAPK pathway. (a) Representative western blot of siRNA-mediated DC-SCRIPT knockdown in immature and R848-stimulated 
dendritic cells (DCs). (B–F) R848-stimulated Ctrl-DC and SC-KD-DC time course for dual-specificity phosphatase (DUSP)1, 4, 5, 6, and 10 (n = 4, mean + SEM). 
(g–J) Phosphorylation and total protein expression of ERK, JNK, and p38 in Ctrl-DCs and SC-KD-DCs after stimulation with R848 (n = 5, mean + SEM). (K,l) 
DUSP6 and DUSP4 expression in Ctrl-DCs and SC-KD-DCs pretreated with UO126 (MEK inhibitor) or vehicle control for 1 h, followed by R848 stimulation (n = 4, 
mean + SEM). Statistics: Student’s paired t test, Ctrl-DCs were compared to SC-KD-DCs at the same time point. *p < 0.05, **p < 0.01. See also Figure S2 in 
Supplementary Material.
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(Figures 2G–J) and flow cytometry (Figure S2 in Supplementary 
Material). Stimulation with R848 led to a peak in phosphoryla-
tion of all three kinases after 30 min in both SC-KD-DCs and 
Ctrl-DCs. DC-SCRIPT knockdown significantly enhanced 
the phosphorylation of all three kinases, with the most potent 
increase in ERK, and only a minor change of phosphorylation 
on p38. As ERK signaling has previously been demonstrated 
to upregulate expression of DUSPs (39, 40), we pretreated the 
cells with a MEK inhibitor prior to stimulation, to investigate 
whether ERK signaling was responsible for the observed effect on 
FigUre 3 | DC-SCRIPT enhances dual-specificity phosphatase (DUSP)4 expression. (a,B) DUSP4 EA-SC binding site track from UCSC Genome Browser.  
(a) The tracks from top to bottom show the DUSP4 gene annotation, and the ChIP-Seq signal for DC-SCRIPT (blue), H3K4me3 (green), H3K27ac (purple), and 
input (gray). (B) Position of the GA-rich motifs identified de novo from this ChIP-Seq dataset or in vitro by cyclic amplification and selection of targets. (c) Topological 
associated domain (TAD) analysis was done using the Hi-C data browser from the Yue-lab at Penn State (http://promoter.bx.psu.edu/hi-c) containing data from Ref. 
(41–43). Highlighted in the figure is a local TAD that only contains the DUSP4 gene, and the EA-SC binding site. The example shown is from GM12878 
(lymphoblastoid B cell line). (D) Luciferase assays with DUSP4 promoter-containing vector with either genomic DNA containing the DUSP4 gene-associated EA-SC 
binding site, or a control piece of DNA located in between the binding site and the DUSP4 TSS of similar length. Some conditions were cotransfected with 
increasing amounts of a DC-SCRIPT expression vector or corresponding amount of empty vector. Firefly luciferase is presented relative to TK renilla luciferase 
control (n = 3, mean + SEM). Statistics: ANOVA with Bonferroni post test. (e,F) Protein expression level of DUSP4 in unstimulated or 6 h R848-stimulated Ctrl-DCs 
and SC-KD-DCs (n = 7, mean + SEM). Statistics: Student’s paired t test. **p < 0.01, ***p < 0.001.
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DUSP4 and DUSP6 expression (Figures 2K,L). Strikingly, pre-
treatment with the inhibitor diminished DUSP6 upregulation, 
while DUSP4 remained unaltered. This suggests that DUSP4 is 
regulated directly by DC-SCRIPT, whereas the effect on DUSP6 
is rather part of an ERK signaling feedback loop.
Dc-scriPT enhances DUsP4 expression
The DC-SCRIPT binding site associated with the DUSP4 gene 
was further validated by ChIP-qPCR in seven additional inde-
pendent donors (Figure S3 in Supplementary Material). The 
binding site displayed enhancer characteristics (high H3K27ac 
and low H3K4me3 binding) and was located 285kB downstream 
of the DUSP4 transcription start site (Figure  3A). Both the 
de novo and the in vitro motif could be found toward the center 
of the binding site (Figure 3B). Intriguingly, this location falls 
within a local topological associated domain (TAD) previously 
found in all 19 different assayed cell lines and 13 different tis-
sues, including immune cells (Figure 3C). Together this would 
suggest that this DC-SCRIPT binding position is an enhancer 
for DUSP4. To further evaluate this, a luciferase vector contain-
ing the DUSP4 promoter and the genomic DNA underlying the 
DUSP4 EA-SC-binding site was generated. For comparison, 
a control vector with a piece of genomic DNA of similar size, 
without the motif, and located between the DUSP4 TSS and 
6Søndergaard et al. IL-10 Regulation by DC-SCRIPT and DUSP4
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the DUSP4 EA-SC binding site was employed. Interestingly, the 
genomic DNA underlying the DUSP4 EA-SC genomic DNA 
lead to a 8.5-fold increase in luciferase activity (Figure  3D). 
Co-transfection with DC-SCRIPT further increased the lucif-
erase signal in a dose-dependent manner (1.8-fold compared 
to no DC-SCRIPT). To confirm the impact of DC-SCRIPT 
expression on DUSP4 at the functional level, DUSP4 protein 
expression was determined in immature and R848-stimulated 
Ctrl-DCs and SC-KD-DCs (Figures 3E,F). In accordance with 
the mRNA expression, DUSP4 protein levels were significantly 
higher in Ctrl-DCs relative to DC-SCRIPT silenced DCs both at 
the immature state and after stimulation. Altogether, these data 
therefore indicate that the DUSP4 gene-associated EA-SC bind-
ing site works as an enhancer, and that DC-SCRIPT expression 
impacts the DUSP4 protein level.
The Dc-scriPT-induced Phenotype  
is Mediated by DUsP4
The most dominant immunological phenotype reported for 
DC-SCRIPT in DCs so far is the major increase in IL-10 pro-
duction following siRNA-mediated knockdown of DC-SCRIPT 
(23, 31). To assess whether the observed change in DUSP4 
expression level could be responsible for this effect on IL-10 
production, we evaluated Ctrl-DCs and SC-KD-DCs ability to 
produce IL-10 after MAPK inhibition and DUSP4 overexpression 
(Figure 4). While inhibition of JNK did not affect IL-10 secretion, 
both inhibition of the upstream kinase of ERK (MEK) and p38 
lead to a major decrease in IL-10 (Figure 4A).
DUSP4 has previously been demonstrated to have a high 
affinity for dephosphorylating ERK (44), and could therefore 
explain the enhanced ERK phosphorylation after DC-SCRIPT 
knockdown. To confirm this in human DCs, we rescued DUSP4 
expression by introducing DUSP4/GFP or GFP in SC-KD-DCs 
using Ctrl-DCs as controls and determined the level of phos-
phorylated ERK (Figures  4B,C; Figure S4 in Supplementary 
Material). Strikingly, rescuing DUSP4 expression changed phos-
phorylation of ERK in the SC-KD-DCs back to wild-type levels. 
As DC-SCRIPT knockdown also had an effect on phosphoryla-
tion of p38, the effect of DUSP4 on p38 phosphorylation was also 
assayed under the same settings (Figures  4D,E). Interestingly, 
like ERK, phosphorylation of p38 was also reduced to wild-
type levels after rescuing DUSP4 in DC-SCRIPT knockdown 
DCs. Finally, rescuing DUSP4 expression in SC-KD-DCs also 
normalized levels of IL-10 production (similar level as Ctrl-DC) 
(Figure 4F).
Dc-scriPT expression in Dcs skews 
naïve T cells Toward Th1 immune 
activation
To determine the impact of DC-SCRIPT expression on the 
cytokine polarization of naïve CD4+ T  cells, we co-cultured 
SC-KD-DCs or Ctrl-DCs with allogeneic naïve CD4+ T cells and 
assayed their cytokine production. Interestingly, the responding 
T cells produced less IFN-γ and more IL-10 upon incubation with 
SC-KD-DCs (Figure 5A). In line with these data, the expression of 
T cell subset restricted transcription factors revealed a significant 
decrease in T-bet (Th1 TF) expressing T cells, while the number 
of GATA3 (Th2 TF) and RORgT (Th17 TF) expressing T  cells 
remained similar (Figure 5B).
Altogether, these data demonstrate that DC-SCRIPT-mediated 
enhancement of DUSP4 expression is responsible for restricting 
ERK and p38 signaling and subsequent IL-10 production by 
professional antigen-presenting DCs under inflammatory condi-
tions (Figure 6), which in turn limits pro-inflammatory CD4+ 
T cell polarization.
DiscUssiOn
Dendritic cells are the sentinels of the immune system, playing 
a decisive role in the balance between immunogenic and tolero-
genic immune responses (10), however, the molecular mecha-
nism of how DCs control production of the anti-inflammatory 
cytokine IL-10 in an inflammatory setting is still unclear. Here, 
we show that DC-SCRIPT, a DC-specific transcription factor in 
the immune system, binds to GA-rich sequences in enhancer- 
and promoter-associated DNA regions for many immune-related 
genes, including an enhancer for the MAPK phosphatase DUSP4. 
Moreover, we show that DC-SCRIPT knockdown limits DUSP4 
expression resulting in an increase in the activity of the MAPK 
signaling pathway and subsequent IL-10 production by DCs. 
In addition, the knockdown of DC-SCRIPT also hindered dif-
ferentiation of naïve CD4+ T cells into pro-inflammatory T cells. 
Altogether, these data show a novel mechanism by which profes-
sional antigen-presenting DCs limit IL-10 production, a pathway 
that needs to be tightly controlled to induce protective immune 
responses (20).
Many different immune cells can produce IL-10 and during 
cancer development, this has mainly been considered detrimen-
tal for successful eradication of the tumor cells due to IL-10’s 
immunosuppressive capabilities on DCs (45) and T  cells (46). 
Previously, we have demonstrated that DC-SCRIPT affects TLR-
mediated IL-10 production in human DCs (23), and described 
that enhanced IL-10 production in SC-KD-DCs was partly 
caused by altered post-translational modifications of NF-κBp65 
leading to increased binding of NF-κBp65 to an IL-10 enhancer 
element (31). In our current ChIP-Seq data, we did not find a 
DC-SCRIPT binding site at the same position as for NF-κBp65 
in the enhancer of the IL-10 gene, i.e., it does not seem that 
DC-SCRIPT is part of the NF-κBp65 DNA binding complex. In 
line with these observations, knockdown of DC-SCRIPT affected 
the phosphorylation status of NF-κB (31), and with the current 
data linking DC-SCRIPT to phosphatases, it may suggest that 
DC-SCRIPT affects NF-κB activation indirectly. In support of 
this, a downstream kinase (MSK1) of the MAPKs ERK and p38 
has been demonstrated to mediate phosphorylation of NF-κBp65 
(47), and ERK has been shown to play a critical role for IL-10 
production in DCs (20).
In the current work, we found that DC-SCRIPT knockdown 
leads to higher DUSP4 expression and that DC-SCRIPT binds 
a GA-rich DNA sequence with enhancer abilities within a local 
DUSP4-TAD. Using luciferase assays, we found that the largest 
enhancing effect was gained by cloning the enhancer close to 
the DUSP4 promoter, while co-transfecting DC-SCRIPT only 
FigUre 4 | DUSP4 expression prevents the DC-SCRIPT-knockdown-mediated change in ERK phosphorylation and IL-10 production. (a) IL-10 protein  
production by Ctrl-DCs and SC-KD-DCs pre-treated with inhibitors for MEK (upstream of ERK), JNK, p38 or with vehicle control and stimulated with R848 (n = 6, 
mean + SEM). (B–e) pERK and pp38 phosphorylation levels of Ctrl-DCs and SC-KD-DCs after overexpression of GFP or DUSP4/GFP by phosphoflow (n = 8, 
mean + SEM). (F) IL-10 protein production by Ctrl-DCs and SC-KD-DCs after overexpression of GFP or DUSP4/GFP (n = 7, mean + SEM). The IL-10 protein data 
have been normalized to account for donor variation and displayed as arbitrary units (SC-KD-DCs + vehicle range: 0.5–4.6 ng/mL) Statistics: Student’s paired t test. 
Where no lines are shown, Ctrl-DCs were compared to SC-KD-DCs at the same time point. *p < 0.05, **p < 0.01, ***p < 0.001. FI, fluorescence intensity; AU, 
arbitrary unit. See also Figure S4 in Supplementary Material.
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led to a subtle (but significant) further increase in the signal. 
These data could indicate that one of the roles of DC-SCRIPT 
in enhancing DUSP4 expression would be to bring the DUSP4 
enhancer in close proximity to the promoter. Currently, only 
little is known about the functional role of DUSP4 in DCs. Gene 
expression analysis has revealed that immune cells express up 
to 17 different DUSPs to various extent, but only one or two 
DUSPs showed high expression in any single cell type (37). 
DUSP4 was predominantly expressed in DCs, and furthermore, 
high DUSP4 expression could distinguish DCs from the closely 
related monocyte-derived macrophages (37). Interestingly, accu-
mulating evidence suggests that cell type-specific transcription 
factors often regulate cell type-specific genes via binding to 
enhancers (48).
FigUre 6 | Model of DC-SCRIPT mediated control of IL-10 production in DCs. In the presence of DC-SCRIPT (left figure), DC-SCRIPT binds an enhancer (E) for 
DUSP4 via a GA-rich motif. This leads to enhanced DUSP4 expression, which limits ERK signaling, and subsequent IL-10 production under inflammatory conditions. 
By contrast, in the absence of DC-SCRIPT (right figure), DUSP4 is only expressed at a low level, thereby enabling higher ERK signaling leading to an increase in 
IL-10 production. X and Y are potential protein partners in the enhancer complex.
FigUre 5 | Knockdown of DC-SCRIPT in DCs polarizes T cells toward 
immunosuppression. Naïve CD4+ T cells were co-cultured with 
SC-KD-DCs or Ctrl-DCs until in a resting state after 10–12 days. Upon 
re-stimulation, the phenotype of the T cells were assayed for (a) 
expression of T cell subset markers by FACS and (B) secreted cytokines 
by ELISA (n = 12 + SEM). Statistics: Student’s paired t test. **p < 0.01, 
***p < 0.001.
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One of DCs main function in the immune system is to educate 
T cells toward pro-inflammatory or anti-inflammatory responses. 
We observed that knockdown of DC-SCRIPT in DCs limited the 
DCs capability to induce pro-inflammatory CD4+ T cells when 
polarized from naïve cells. These T  cells produced less IFN-γ 
and more IL-10, and in line with these data, the number of T-bet 
expressing T  cells was also reduced. Surprisingly, even though 
DC-SCRIPT knockdown leads to increased production of IL-10, 
and IL-10 is a potent inducer of anti-inflammatory Tr1 cells (11), 
preliminary experiments did not show any skewing of naïve 
T  cells into Tr1 cells (data not shown). As DC-SCRIPT levels 
affect a DC’s capacity to induce inflammatory Th1 responses, one 
could consider monitoring DC-SCRIPT expression in DCs used 
in vaccination studies.
In summary, the transcription factor DC-SCRIPT binds 
regulatory DNA sequences linked to genes involved in the 
immune system and the MAPK pathway, including MAPK 
phosphatases. We identify regulation of expression of the MAPK 
phosphatase DUSP4 as the mode of action through which 
DC-SCRIPT restricts the expression of the crucial immune- 
inhibitory cytokine IL-10 in DCs. These data help to delineate 
the mechanisms that govern DCs unique molecular function, 
and its central role in controlling immune responses. As DC 
immunotherapy is a promising approach to treat cancer patients, 
specifically targeting tumor cells and having only few side 
effects (49, 50), much research has focused on which pattern- 
recognition receptor ligands or cytokine-cocktails would generate 
a DC-phenotype with a favorable cytokine profile, often focus-
ing on high IL-12 and low IL-10 levels (51–53). The current data 
showing IL-10 being actively inhibited by DC-SCRIPT-induced 
phosphatases imply that maturing DCs with a combination of 
immune-activating adjuvants and either kinase inhibitors or 
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phosphatase inducers may be beneficial to improve DC-based 
immunotherapy.
MaTerials anD MeThODs
generation of human Monocyte-Derived 
Dendritic cells (moDcs)
Human moDCs were generated from PBMCs as described previ-
ously (54). Buffy coats were obtained from healthy volunteers 
(Sanquin, Nijmegen, The Netherlands) after informed consent 
and according to institutional guidelines. Plastic-adhered mono-
cytes were cultured for a total of 6 days in RPMI 1640 medium 
(Life Technologies) supplemented with 1% ultra-glutamine 
(Cambrex), 0.5% antibiotic–antimycotic (Invitrogen), 10% (v/v) 
FCS (Greiner Bio-one), IL-4 (300 U/mL), and GM-CSF (450 U/mL) 
(both from Cellgenix). On day 3, moDCs were supplemented 
with new IL-4 (300 U/mL) and GM-CSF (450 U/mL).
small interfering rna (sirna)-Mediated 
Knockdown
On day 3–4 of DC differentiation, cells were harvested and 
subjected to electroporation. For DC-SCRIPT silencing, a 23-nt 
custom ZNF366 siRNA termed SC38 targeting the DC-SCRIPT 
gene at position 2,349–2,369 was used (Thermo Scientific). siRNA 
ON-TARGETplus Non-Targeting siRNA#1 (Thermo Scientific) 
was used as control. Cells were washed twice in PBS and once 
in OptiMEM without phenol red (Invitrogen). A total of 10 µg 
siRNA was transferred to a 4-mm cuvette (Bio-Rad), and 10 × 106 
DCs were added in 200 µL OptiMEM and incubated for 3 min 
before being pulsed with an exponential decay pulse at 300  V, 
150 μF, in a Genepulser Xcell (Bio-Rad), as previously described 
(55). Immediately after electroporation, the cells were transferred 
to pre-heated (37°C) phenol red-free RPMI 1640 culture medium 
supplemented with 1% ultra-glutamine, 10% (v/v) FCS, IL-4 
(300 U/mL), and GM-CSF (450 U/mL).
stimulations and inhibitors
Immature DCs were stimulated with 4 µg/mL R848 (Axxora). In 
some experiments, DCs were pre-treated 1–2 h with one of the 
following inhibitors: 4 µM UO126 (MEK1/2, LC Laboratories), 
2.5 µM SB203580 (p38, LC laboratories), 5 µM SP600125 (JNK, 
Tocris Bioscience).
rna isolation, reverse Transcription,  
and Quantitative Pcr
Total RNA was isolated from cells using Trizol (Ambion). RNA 
quantity and purity were determined on a NanoDrop spectro-
photometer. RNA was treated with DNase I (amplification grade; 
Invitrogen) and reverse transcribed into cDNA by using random hex-
amers and Moloney murine leukemia virus reverse transcriptase 
(Invitrogen). mRNA levels for the genes of interest were determined 
with a CFX96 sequence detection system (Bio-Rad) with SYBR 
Green (Roche) as the fluorophore and gene-specific  oligonucleotide 
primers. Primers used are as follows (forward, reverse): DC- 
SCRIPT (ZNF366): (5′-AAGCATGGAGTCATGGAG-3, 5′-TTC 
TGAGAGAGGTCAAAGG-3′), PGK1: (5′-CAAGAAGTATGCT 
GAGGCTGTCA-3, 5′-CAAATACCCCCACAGGACCAT-3′), DU 
SP4: (5′-AGTGGAAGATAACCACAAGG-3, 5′-GCTTAACGA 
ACTCGAAGG-3′), DUSP6: (5′-GATCACTGGAGCCAAAAC-3, 
5′-CAAGCAATGTACCAAGACAC-3′), DUSP1: (5′-AGTAC 
CCCACTCTACGATCAGG-3, 5′-GAAGCGTGATACGCACTG 
C-3′), DUSP5: (5′-TGTCGTCCTCACCTCGCTA-3, 5′-GGGCT 
CTCTCACTCTCAATCTTC-3′), DUSP10: (5′-TTTGAAGAGG 
CTTTTGAGTT-3, 5′-GGGAGATAATTGGTCGTTT-3′). Reac-
tion mixtures and program conditions were used as recommended 
by the manufacturer (Bio-Rad). Quantitative PCR data were 
analyzed with the CFX Manager software (Bio-Rad) and checked 
for correct amplification and dissociation of the products. mRNA 
levels of the genes of interest were normalized to mRNA levels 
of the housekeeping genes GAPDH or PGK1 and were calculated 
according to the cycle threshold method (56).
elisa
Secreted IL-10 was measured using the human IL-10 ready-set-
go kit (eBioscience) in the supernatants of 16–24  h-stimulated 
DCs or T cells. Secreted IFN-γ was measured using IFN-γ mono-
clonal antibodies; coating clone 2G1, detection Ab-biotin, clone 
XMG1.2 (both Thermo Fisher).
Western Blotting
Monocyte-derived dendritic cells were lysed in a concentration 
of 106/100 μL 4°C cold lysis buffer consisting of 62.5  mM Tris 
(pH 6.8, Sigma-Aldrich), 1% SDS (Invitrogen), and freshly 
added complete protease inhibitor cocktail (Roche), 1 mM PMSF 
(Sigma-Aldrich), and for phosphorylation-specific western blot: 
phosphatase inhibitors 1  mM Na3VO4 (Sigma-Aldrich) and 
10  mM NaF (Merck). Cell lysates were mixed 1:4 with sample 
buffer containing 5% glycerol (Invitrogen), 6% SDS, 125  mM 
Tris–HCl (pH 6.8), 0.1 mg/mL bromophenol blue (Gebr. Schmid), 
and 10% 2-ME (Sigma-Aldrich), heated at 95°C for 5 min, and 
then cooled on ice. The proteins were resolved by electrophoresis 
on a 10% polyacrylamide gel (ratio of acrylamide to bisacryla-
mide, 37.5:1) and transferred to Protran nitrocellulose transfer 
membranes (Amersham) at 4°C. The following Abs were used for 
staining in TBS with 0.1% tween 20 (TBST) and 5% BSA (all from 
Cell Signaling Technology): rabbit anti-DUSP4 (1:1,000 dilution, 
clone: D9A5), rabbit anti-ERK (1:1,000 dilution, cat: 9102), 
rabbit anti-pERK (Thr202/Tyr204) (1:2,000 dilution, clone: 
D13.14.4E), rabbit anti-JNK (1:1,000 dilution, cat: 9252), rabbit 
anti-p38 (1:2,000 dilution, clone: D13E1), and rabbit anti-p-p38 
(Thr180/Tyr182) (1:1,000 dilution, clone: D3F9). Goat anti-DC-
SCRIPT were used for staining in PBS with 0.1% tween 20 and 1% 
skimmed milk powder (Campina) and 3% BSA (1:600 dilution, 
cat: AF4707, R&D Systems). Mouse anti-p-JNK (Thr183/Tyr185) 
were used for staining in TBST with 2% skimmed milk powder and 
2% BSA (1:250 dilution, clone: G9, Cell Signaling Technology). 
Membranes were blocked for 1 h at room temperature, stained 
overnight with primary Abs [including rabbit anti-actin (1:2,000 
dilution, clone: 20–33, Sigma-Aldrich) or rat anti-tubulin (1:2,000 
dilution, clone: YOL1/34, Novus Biologicals)], and stained for 1 h 
at room temperature with corresponding secondary Abs (diluted 
1:5,000): goat anti-mouse IgG IRDye 800CW, goat anti-rabbit 
IgG IRDye 800CW, donkey anti-goat IgG IRDye 800CW, donkey 
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anti-rabbit IgG IRDye 680 (all Li-cor Biosciences), and goat anti-
rat Alexa Fluor 680 (Invitrogen). Membranes were scanned by 
using an Odyssey Infrared Imaging System (Li-cor Biosciences).
Flow cytometry of Dcs
For phosphorylation-specific flow cytometry, paraformaldehyde 
(Merck) was added directly to the culture medium at a final 
concentration of 1.6% at the end of the stimulation. Cells were 
fixed for 10  min at room temperature. Subsequently, culture 
medium was aspirated, resuspended in 100% ice-cold MeOH 
(Boom) and incubated at −20°C overnight, followed by extensive 
washing (4×) in PBS with 1% BSA, 0.05% NaN3 (Merck). Cells 
were blocked and stained in PBS with 1% BSA, 0.05% NaN3 
(Merck), and 2% human serum (Sanquin), using 1:200 diluted 
pERK, 1:400 diluted p-p38 Abs, or isotype control (rabbit IgG, 
Jackson Immuno Research). Cells were stained with primary 
Ab/isotype control for 45 min on ice, followed by 30 min on ice 
with a secondary PE-Cy5.5 goat anti-rabbit IgG Ab (Invitrogen, 
cat# L42018). Data were acquired on an FACSCyan (Beckman 
Coulter). Isotype controls gave a staining intensity similar as 
unstimulated moDCs, indicating that blocking conditions were 
sufficient to avoid unspecific staining (data not shown). Viability 
was measured using a fixable viability dye eFluor780 (eBiosci-
ence), following the manufacturers instructions. Data were 
analyzed using FlowJo (Treestar).
chromatin immunoprecipitation 
sequencing
Chromatin immunoprecipitation was performed as previously 
described (31), using 20  µg goat-α-DC-SCRIPT Ab (R&D 
Systems). 10 ng of input or ChIP-enriched DNA was end-paired 
using T4 DNA polymerase, E. coli DNA Pol I large fragment 
(Klenow polymerase, New England Biolabs), and T4 polynu-
cleotide kinase (New England Biolabs), followed by purification 
using the QIAquick PCR purification kit (Qiagen). Subsequently, 
DNA was dA-tailed using the Klenow fragment (3′ to 5′ exo 
minus, New England Biolabs), followed by purification using 
the MinElute Reaction Cleanup kit (Qiagen). Next, DNA was 
ligated to multiplex NEXTflex adapters (Bioo Scientific). IP and 
input DNA were purified by the MinElute reaction Cleanup kit, 
and amplified by PCR using the KAPA HiFi HotStart ReadyMix 
PCR kit (KAPA Biosystems) with the following program: 45 s at 
98°C for initial denaturation, 15 s at 98°C, 30 s at 65°C, 30 s at 
72°C for four cycles, followed by 1 min at 72°C for final exten-
sion. Removal of excess adaptors and selection of 300 bp bands 
was done using 2% E-Gel SizeSelect Agarose Gels (Invitrogen). 
Adapter-modified DNA fragments were enriched by PCR using 
the KAPA HiFi HotStart ReadyMix PCR kit for 8–10 cycles with 
the aforementioned program. To get rid of the 120 bp adapter 
dimer, the PCR product was purified using Ampure beads 
(Beckman Coulter). Libraries were sequenced on the Illumina 
HiSeq 2000. H3K4me3 and H3K27ac antibodies were exten-
sively characterized1 and used for ChIP according to standard 
BLUEPRINT protocols.1 
1 www.blueprint-epigenome.eu (Accessed: April 18, 2018).
chiP-seq Data Processing
Peaks were called using the algorithm MACS2 version 
2.0.10.20120913 (57) with default settings. In order to account 
for donor variation and dynamics, three donors were assayed, 
using immature, 1 h-, and 24 h-stimulated DCs. Peaks present in 
all three donors were determined using intersect with BEDTools 
version 2.20.1 (58), and only DC-SCRIPT peaks present in all 
three donors were used for subsequent analysis. All ChIP-Seq data 
have been submitted to the GEO database (accession number: 
GSE78923) k-Means clustering (k = 6, Euclidean distance) and 
heatmaps were generated using Fluff (59). De novo motif analysis 
was done using GimmeMotifs version 0.8.6 (34). The motif was 
trimmed to remove low information content containing bases.
cyclic amplification and selection  
of Targets
Human DC-SCRIPT was cloned in the pCATCH vector (60), 
as BamHI-XbaI inserts. In vitro transcription/translation was 
performed with the TNT T7 Quick Coupled Transcription/
Translation System (Promega) according to the manufacturer’s 
recommendations, using 1 µg of DNA as input. Transcription/
translation took place at 30°C for 90 min. 10% of the reaction was 
tested by western blot analysis to verify protein production, while 
20% was used in each CAST round.
Oligo-nucleotides carrying defined ends and a 21-nt region of 
degeneracy (5′-GCCTCCATGGACGAATTCTGT-(N)21-AGCG 
GATCCCGCATATGACCG-3′) and PCR primers (forward: 5′- G 
CCTCCATGGACGAATTCTGT-3′ and reverse: 5′-CGGTCAT 
ATGCGGGATCCGCT-3′) were used during CAST. As a first 
step, double-stranded oligo-nucleotides were prepared as follows. 
8.5  µg of the degenerative nucleotides were mixed with 4.3  µg 
of the reverse primer in 50  µL of Tris–HCl (100  mM, pH 8) 
and heated at 80°C, then cooled down slowly to 4°C. 2 µL of the 
hybridized oligo-nucleotides were used together with 2 U of the 
Klenow fragment of DNA polymerase I (37°C for 1 h) to create 
dsDNA. dsDNA was precipitated and used in the first round 
of CAST. Each CAST round was performed in binding buffer 
containing 30 mM HEPES pH 7.4, 100 mM NaCl, 0.01% NP40, 
0.01 mg/mL BSA, 0.05 mM ZnSO4, 2 mM MgCl2, 0.6 mM PMSF, 
and 10% glycerol. In brief, 500 µL of binding buffer were mixed 
with 20% in  vitro transcribed/translated proteins and DNA 
and incubated for 30 min at 4°C. Then 10 µL of Protein G beads 
and 3 µg of mouse M2 anti-FLAG mAb (Sigma) were added and 
incubated overnight. Precipitated dsDNA was used for the first 
round of CAST, or 80% of the PCR reaction for the subsequent 
rounds. After the binding reaction, Protein G beads were washed 
twice with 600 µL of binding buffer and resuspended in 20 µL 
of 5 mM EDTA pH 8 for 10 min at 90°C. Beads were pelleted 
and supernatant was used for PCR. 20% of the PCR reaction 
was tested on gel to verify DNA precipitation and amplification 
by CAST.
PCR reactions for CAST were performed using 100  ng of 
forward and reverse primer, 0.5 mM of dNTPs, 5 mM of MgCl2, 
and 2.5  U of Taq polymerase with 58°C as an annealing tem-
perature. The number of PCR cycles was kept to a minimum, 
i.e., 15 cycles, in the first two rounds. Minimal PCR amplification 
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helped to reduce the amplification of non-specific oligo-
nucleotides and the formation of hetero-duplexes that resulted 
from the re-annealing of products that were mismatched in the 
21-bp central-region. After the third round, however, 20 cycles 
of PCR ensured good amplification and abundance of specific 
oligo-nucleotides. Sequences from four rounds of CAST were 
used as input for MEME (35) to generate a consensus sequence 
for DC-SCRIPT.
genomic regions enrichment of 
annotations Tool
Genomic Regions Enrichment of Annotations Tool analysis 
was done in version 3.0.0 as previously described (36), with 
DC-SCRIPT binding sites with an H3K4me3 and/or H3K27ac 
histone mark, and containing the GA-rich motif. Default set-
tings were employed, i.e., basal plus extension: proximal: 5.0 kb 
upstream, 1.0  kb downstream, plus distal: up to 1,000.0  kb. 
Statistical significance is based on false discovery rate (cutoff: 
0.05). Displayed data contains minimum three genes in each GO.
luciferase assays
The DNA sequence underlying the ChIP-Seq-identified DUSP4 
EA-SC-binding site was cloned into a pGL4.10 luciferase vec-
tor (Promega) behind a DUSP4 promoter. For comparison, a 
control pGL4.10 vector with the DUSP4 promoter and a piece of 
genomic DNA of similar size, and located between the DUSP4 
TSS and the DUSP4 EA-SC binding site was also generated. 
These vectors were transfected into HEK293 [ATCC, tested to 
be mycoplasma free using mycoalert mycoplasma detection kit 
(Lonza), and used between passages 2–15 after thawing] together 
with a renilla control vector (pRL-TK, Promega) and increas-
ing amounts of a pCATCH-DC-SCRIPT expression vector. 
HEK293s were plated 24 h before transfection using metafectene. 
Cells were harvested after 24 h, and cell lysates were analyzed 
for luminescence according to the manufacturer’s protocol (Dual 
Luciferase Reporter assay, Promega) using a Victor3 luminom-
eter (PerkinElmer). Relative light units were calculated after 
correction for transfection efficiency based on the activity of the 
cotransfected pRL-TK.
Overexpression of DUsP4
To generate a DUSP4/GFP expression vector, DUSP4 
(NM_001394) was cloned into the expression vector pEGFP-N3 
(Clontech, Mountain View, CA, USA), using the restriction 
enzyme sites BglII and BamHI. As a control, the empty pEGFP-
N3 vector was used. Immature SC-KD-DCs and Ctrl-DCs were 
harvested on day 6 and electroporated using the Neon transfection 
system (Invitrogen) according to the manufacturer’s instructions. 
Briefly, 106 DCs were mixed with 5 µg DNA, and electroporated 
with two pulses of 1,000 V for 40 ms. Subsequently, DCs were 
seeded in microtiter plates and rested for 5–6 h until GFP was 
visible. The cells were subsequently stimulated and used for 
functional assays.
naïve T cell Polarization
Naïve T  cells were isolated from buffy coats using magnetic-
associated cell sorting, and negative selection, by depleting 
cells expressing CD8a, CD14, CD15, CD16, CD19, CD36, 
CD56, CD132, TcRγ/δ, and CD235a (CD4+ T Cell isolation kit, 
human, Miltenyi), and CD45RO [anti-CD45RO-PE (DAKO) 
plus anti-PE microbeads (Miltenyi)]. Purity was checked using 
CD3-FITC (BD), CD4-PE-Cy7 (BioLegend), CD45RA-APC-Cy7 
(BioLegend), and CD45RO-PE and determined to be >97% of 
CD3+ CD4+ CD45RO− CD45RA+ T cells.
SC-KD-DCs or Ctrl-DCs were stimulated for 16 h with R848, 
washed and counted, before co-culturing with naïve CD4+ 
T cells in a ratio of 5,000:20,000 DC:T. The super antigen SEB 
(Sigma-Aldrich) was added at 10 pg/mL. After 5, 7, and 9 days of 
co-culture, the T cells were split 1:2 and recombinant human IL-2 
were added at a final concentration of 20 U/mL. On day 11, the 
T cells are in a resting state, which can be seen in a light micro-
scope by the T cell clusters falling apart and cells are rounded. The 
resting T cells were assayed for intracellular transcription factor 
expression using the cytofix/cytoperm kit (BD). Prior to permea-
bilization cells were stained with fixable viability dye eFluor780 
(eBioscience). Antibodies used for staining were: anti-human 
Gata-3-Alexa Fluor488, anti-human RORgamma(t)-APC, and 
anti-human T-bet-PE (all eBioscience).
For cytokine production, T  cells were harvested, counted, 
and 100,000 cells re-plated in a 96-well round bottom plate, 
followed by addition of 100,000 anti CD3/CD28 beads (Gibco). 
Supernatant was harvested after 24 h and assayed by ELISA. Data 
presented in the figure consists of two T cell donors and six DC 
donors.
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